Literature DB >> 26859205

68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.

Ingo Einspieler1, Robert Tauber, Tobias Maurer, Markus Schwaiger, Matthias Eiber.   

Abstract

Ga prostate-specific membrane antigen (PSMA)-HBED-CC PET/CT in a patient with a history of both prostate cancer (PC) and renal cell cancer (RCC) shows high PSMA expression in the residual right seminal vesicle suggestive of local recurrence of PC as well as suspected PSMA-positive mediastinal, retroperitoneal, and iliac lymph nodes. Regarding the latter, biopsy revealed lymph node metastases from RCC excluding PC metastases. This case exemplarily demonstrates that high PSMA expression in RCC metastases can potentially mimic PC metastases. Thus, for accurate interpretation of imaging results in PC patients with additional primary tumors, knowledge of PSMA expression of non-PC tissue is necessary.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26859205     DOI： 10.1097/RLU.0000000000001128

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  9 in total

1.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

2.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 3.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

Review 4.  A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Authors:  Thomas Ahn; Matthew J Roberts; Aous Abduljabar; Andre Joshi; Marlon Perera; Handoo Rhee; Simon Wood; Ian Vela
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

5.  The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma.

Authors:  Sheliyan Raveenthiran; Rachel Esler; John Yaxley; Sam Kyle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-23       Impact factor: 9.236

Review 6.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 7.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

8.  Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.

Authors:  Ansje S Fortuin; Roger Brüggemann; Janine van der Linden; Ilia Panfilov; Bas Israël; Tom W J Scheenen; Jelle O Barentsz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-06

Review 9.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.